Levofloxacin Prophylaxis in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplantation Recipients Does not Prevent Infective Complications and Infections-related Deaths - Takeaways - MDSpire

Levofloxacin Prophylaxis in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplantation Recipients Does not Prevent Infective Complications and Infections-related Deaths

  • By

  • Davide Leardini

  • Giacomo Gambuti

  • Edoardo Muratore

  • Francesco Baccelli

  • Francesca Gottardi

  • Francesco Venturelli

  • Tamara Belotti

  • Arcangelo Prete

  • Marco Fabbrini

  • Patrizia Brigidi

  • Silvia Turroni

  • Riccardo Masetti

  • December 3, 2024

  • 0 min

Share

  • 1

    Levofloxacin prophylaxis in pediatric allo-HCT does not significantly improve overall survival or reduce infection-related complications.

  • 2

    Patients receiving levofloxacin showed a higher incidence of quinolone-resistant bacterial strains compared to those without prophylaxis.

  • 3

    No significant differences were observed in acute graft-versus-host disease incidence between levofloxacin and non-levofloxacin groups.

  • 4

    Gut microbiota analysis revealed lower abundance of certain bacteria in patients receiving levofloxacin at neutrophil engraftment.

  • 5

    Current guidelines provide weak recommendations against routine levofloxacin use in pediatric allo-HCT due to limited evidence.

Original Source(s)

Levofloxacin Prophylaxis in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplantation Recipients Does not Prevent Infective Complications and Infections-related Deaths

  • by Davide Leardini, Giacomo Gambuti, Edoardo Muratore, Francesco Baccelli, Francesca Gottardi, Francesco Venturelli, Tamara Belotti, Arcangelo Prete, Marco Fabbrini, Patrizia Brigidi, Silvia Turroni, Riccardo Masetti

  • December 3, 2024

Related Content

Insights from Multi-Omics on Maternal-Fetal Immune Tolerance in Recurrent Pregnancy Loss: Mechanisms, Integration Challenges, and Clinical Implications

The mechanism of gut microbiota in septic cardiomyopathy based on the bulk transcriptome and Mendelian randomization analysis

An NIH whistleblower warning